학술논문
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
Document Type
article
Author
Kim, Youn H; Prince, H Miles; Whittaker, Sean; Horwitz, Steven M; Duvic, Madeleine; Bechter, Oliver; Sanches, Jose A; Stadler, Rudolf; Scarisbrick, Julia; Quaglino, Pietro; Zinzani, Pier Luigi; Wolter, Pascal; Eradat, Herbert; Pinter-Brown, Lauren C; Ortiz-Romero, Pablo L; Akilov, Oleg E; Trotman, Judith; Taylor, Kerry; Weichenthal, Michael; Walewski, Jan; Fisher, David; McNeeley, Marise; Gru, Alejandro A; Brown, Lisa; Palanca-Wessels, M Corinna; Lisano, Julie; Onsum, Matthew; Bunn, Veronica; Little, Meredith; Trepicchio, William L; Dummer, Reinhard
Source
Subject
Language
Abstract
IntroductionMycosis fungoides (MF), the most common type of cutaneous T-cell lymphoma, can lead to disfiguring lesions, debilitating pruritus and frequent skin infections. This study assessed response to brentuximab vedotin in patients with MF in the phase III ALCANZA study.MethodsBaseline CD30 levels and large-cell transformation (LCT) status were centrally reviewed in patients with previously-treated CD30-positive MF using ≥2 skin biopsies obtained at screening; eligible patients required ≥1 biopsy with ≥10% CD30 expression. Patients were categorised as CD30min